Arrowhead Pharmaceuticals (ARWR) Scheduled to Post Quarterly Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 26th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.63) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Arrowhead Pharmaceuticals Trading Up 1.4 %

NASDAQ:ARWR opened at $18.54 on Friday. The stock’s 50 day simple moving average is $19.86 and its 200-day simple moving average is $23.22. Arrowhead Pharmaceuticals has a 12-month low of $17.05 and a 12-month high of $39.83. The firm has a market cap of $2.30 billion, a P/E ratio of -3.97 and a beta of 0.93.

Analyst Ratings Changes

A number of equities analysts have commented on ARWR shares. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $62.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $45.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.